Meeting
2020 ASCO Virtual Scientific Program
Adding precision to 2018 ASCO/CAP HER2 testing guidelines in breast cancer with genomic profiling.
Authors
Adam Brufsky
Magee-Womens Hospital of UPMC, Pittsburgh, PA
Adam Brufsky , Jennifer A. Crozier , Paul J. Chuba , Sung Ho Lee , Andrea Menicucci , Heather M. Kling , Erin Yoder , William Audeh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3570)
DOI
10.1200/JCO.2020.38.15_suppl.3570
Abstract #
3570
Poster Bd #
300
Abstract Disclosures
Similar Posters
First Author: Natália Polidorio
Poster
2011 ASCO Annual Meeting
![Detection of HER2 status of circulating tumor cells and disseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology [CEE]).](https://d201v5jt9ylckg.cloudfront.net/102/6661/59677/59677_poster_pv.jpg)
Detection of HER2 status of circulating tumor cells and disseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology [CEE]).
First Author: S. Krishnamurthy
Poster
2023 ASCO Annual Meeting
Artificial intelligence–powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score.
First Author: Seunghwan Shin
Poster
2023 ASCO Annual Meeting
HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.
First Author: Joshua Z. Drago